There are two different test categories for liquid biopsies, of which one is based on the type of material analyzed in the test and the other is based on the type of analysis that is performed to detect or monitor cancer. On the basis of material type, liquid biopsies can be segmented into analysis of tumor cells, analysis of free DNA, analysis of Exosomal DNA, and analysis of miRNAs. On the basis of analysis type, liquid biopsies can be segmented into small-scale mutation analysis and targeted deep sequencing, analysis of structural changes, large-scale mutation analysis by next-generation sequencing, and analysis of copy number alterations.
Statistics:
The global liquid biopsy market is estimated to account for US$ 3,535.1 Mn in terms of value by the end of 2027.
Global Liquid Biopsy Market: Drivers
Increasing preference for non-invasive diagnostic procedures is expected to boost growth of the global liquid biopsy market over the forecast period. Liquid biopsy offers non-invasive diagnostic tests for detecting cancer. It results in lower morbidity compared to conventional biopsy. Moreover, liquid biopsy can offer a better insight of all the tumor profiles and genetic mutations in a patient. These advantages are expected to boost demand for liquid biopsy over the forecast period.
Global Liquid Biopsy Market: Opportunities
Cooperation among bioinformatics specialists, biochemists, and physicians is required to enhance the adoption of liquid biopsy. Parallel investigation of conventional biopsy and liquid biopsy is required to assess the efficacy of liquid biopsy in diagnosis of cancer.
Global Liquid Biopsy Market: Restraints
Access to limited number of genes is expected to hinder growth of the market. Tissue biopsy allows oncologists and doctors to assess multiple genes simultaneously. However, in liquid biopsy, blood and urine tests provides access to one gene at a time, which might not provide accurate companion diagnosis to start the treatment.
Key Takeaways:
The CTC (Circulating Tumor Cells) segment in the global liquid biopsy market was valued at US$ 416.7 Mn in 2019 and is expected to reach US$ 1,710.8 Mn by 2027 at a CAGR of 19.3% during the forecast period. Increasing prevalence of cancer is a major factor propelling growth of the global liquid biopsy market over the forecast period.
The Blood sample segment held dominant position in the global liquid biopsy market in 2019, accounting for 93.6% share in terms of value, followed by urine sample segment. Increasing preference for non-invasive diagnostic procedures is expected to boost growth of the global liquid biopsy market over the forecast period
Market Trends
The adoption of liquid biopsy for diagnosis of lung cancer is increasing in the recent past. Physicians are relying on blood test to detect lung cancer, especially for the patients with non-small cell lung cancer.
The adoption of Artificial Intelligence (AI) in liquid biopsy is rapidly increasing. For instance, Freenome, an AI genomics company based in the U.S., is focused on developing blood tests to detect the body’s early-warning signs of cancer, using AI. In October 2018, the company presented early data in R&D for using machine learning to detect colorectal cancer at its earliest stages.
Global Liquid Biopsy Market: Competitive Landscape
Major players operating in the global liquid biopsy market include, Biocept, Inc., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation.
Global Liquid Biopsy Market: Key Developments
- February 2020: QIAGEN N.V launched its FFPE and liquid biopsy PIK3CA diagnostics in Europe as an aid in identifying breast cancer patients with a phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) mutation
- January 2020: Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical company, announced completing the development and manufacturing of its reference lab cancer liquid biopsy platform for canine cancers
Segmentation
Scope of the report
- Liquid Biopsy Market, By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- Liquid Biopsy Market, By Sample Type:
- Blood
- Urine
- Others
- Liquid Biopsy Market, By Disease Indication:
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- Liquid Biopsy Market, By End User:
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- Liquid Biopsy Market, By Region:
- North America
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- Blood
- Urine
- Others
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- U.S.
- Canada
- Latin America
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- Blood
- Urine
- Others
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- Blood
- Urine
- Others
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- Blood
- Urine
- Others
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- Blood
- Urine
- Others
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Biomarker Type:
- CTC (Circulating Tumor Cells)
- ctNA (Circulating Tumor Nucliec Acids)
- Exosomes
- By Sample Type
- Blood
- Urine
- Others
- By Disease Indication
- Lung Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Institutes
- Academic Institutes
- Diagnostic Centers
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Biocept, Inc. *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Qiagen N.V
- Trovagene, Inc.
- Janssen Global Services, LLC
- MDxHealth SA
- Natera, Inc.
- F. Hoffmann-La Roche Ltd.
- Silicon Biosystems
- Pathway Genomics Corporation
- Sysmex Corporation
“*” marked represents similar segmentation in other categories in the respective section.
